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Objective. The aim of this article is to review the published English literature on aetiology, pathology, clinical presenta-
tion, diagnostic methods and treatment of renal vein thrombosis.
Materials and methods. We searched the published literature from Medline & Pubmed using keywords renal vein throm-
bosis, anti-phospholipid syndrome and nephrotic syndrome. Data was extracted from individual case reports, case series,
articles on pathology, diagnostic tests, treatment modalities, and previous reviews. Case reports which did not add any new
information were excluded.
Results. We selected 60 references based on the above criteria. Renal vein thrombosis is relatively rare. CT angiography is
considered the investigation of choice. Alternatives include MR angiography or renal venography in highly selected
patients. As the condition is relatively uncommon, consensus on the best form of therapy for this condition has been
slow to evolve. The trend in management has shifted to non-surgical therapies particularly systemic anticoagulation except
in highly selected group of patients.
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The termrenal vein thrombosis (RVT) is used todescribe
presence of thrombus in the major renal veins or their
tributaries. This conditionmay either presentwith acute
symptoms or go unnoticed because of lack of symptoms
until a complication like pulmonary embolism or wors-
ening renal function, draws attention to it.
As early as the 5th century BC, Hippocrates and an-
cient Knidian physicians of Asia Minor were familiar
with a renal disease resembling RVT.1 Rayer, a French
nephrologist, was the first to describe RVTand its asso-
ciation with proteinuria in 1840.2 RVT can occur in in-
trauterine life, mostly due to the presence of Factor V
Leiden.3 RVT is also one of the commonest causes
of venous thrombosis in neonates usually following
severe dehydration or prolonged hypotension.4,5
Although trauma, infection and malignancies were
considered to be the predominant causes of this
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and adults is most commonly associated with ne-
phrotic syndrome.6 The exact incidence of RVT due
to other causes is not known but the incidence in
nephrotic syndrome and membranous nephropathy,
the commonest causes of RVT, ranges from 5e62%.7
Males are affected more commonly than females.
There is no racial predilection. Almost two thirds of
patients have bilateral renal vein involvement. In
cases of unilateral thrombosis the left renal vein is
affected more commonly than the right. RVT may
resolve spontaneously without any complication or
result in hypertension and renal failure.8
We present a review of the English literature per-
taining to the aetiological factors, patho-physiological
mechanisms underlying the thrombotic process, vari-
ous diagnostic techniques employed in establishing
the diagnosis and therapeutic options for this rela-
tively uncommon vascular complication.
Material and Methods
We searched the literature from the Medline &
Pubmed using keywords renal vein thrombosis,rved.
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drome. The articles selected included individual
case reports, case series, articles on pathology, diag-
nostic tests and treatment modalities. We also re-
viewed nephrology text books for any additional
information to make this review as comprehensive
as possible. However, the case reports which did not
add any new information were omitted.
Results
Based on our literature search we selected 60 most ap-
propriate and informative references as listed in biblio-
graphy covering various aspects of this condition as
presented below.
Pathology
Rudolf Virchow in 1956, was the first to describe the
pathophysiology of venous thrombosis involving
a combination of three interrelated factors; damage
to the vessel wall (endothelial damage), slowing down
of the blood flow (stasis), and hyper-coagulability
of the blood, popularly known as Virchow’s Triad. Al-
though a single abnormality may occasionally be suf-
ficient to precipitate thrombosis, in majority of the
cases, a combination of more than one factor promotes
venous thrombosis.9 It is evident from review of the
literature that causes and mechanisms of RVT are no
different from venous thrombosis elsewhere in the
body and are listed in Table 1.
Endothelial damage
Causes of endothelial damage as listed are self
explanatory. Homocystinuria is an in-born error of
the trans-sulfuration pathway, which predisposes to
RVT due to high levels of homocystine causing endo-
thelial damage. 10,11
Stasis
RVT in severely dehydrated neonates/infants results
from volume depletion and consequent reduction in
the circulatory blood volume. Blood flow to the kid-
neys is diverted to other organs resulting in sluggish
flow through the renal veins leading to thrombosis.
RVT is also known to occur in the absence of clinically
obvious shock e.g. following neonatal distress and
placement of central venous catheters.12 Other causes
include kinking of the renal vein or compression by
pathological processes in the retroperitoneum.
Eur J Vasc Endovasc Surg Vol 34, August 2007Hypercoagulability
Patients with nephrotic syndrome are at increased risk
of developing thromboembolism, the most common of
which is RVT.13 RVT results from a hypercoagulable
state caused by the heavy proteinuria. Loss of proteins
in nephrotic syndrome results in decreased osmotic
pressure. Reduction in the osmotic pressure stimulates
the synthesis of proteins in the liver including fibrino-
gen and beta-thromboglobulin. Additionally increase
in platelet count, enhanced platelet aggregation, reduc-
tion in coagulation inhibiters especially antithrombin
III, and functional protein S promote thrombosis.14
Factor V Leiden and mutations of prothrombin
gene (G20210A) together constitute the most common
hereditary hypercoagulable states. The heterozygous
mutation is present in 5% of the general population
and 45% to 63% of a thrombophilic population. These
two conditions are also known to cause congenital
stroke and RVT.15
Antiphospholipid Syndrome (APS) first described
in the early 80 s, is characterised by the presence of
anti-phospholipid antibodies (APA), arterial and ve-
nous thrombosis, recurrent abortion and/or thrombo-
cytopenia.16 This is probably themost common cause of
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wise healthy individuals and 35e40% of patients
with SLE. Anti-phospholipid antibodies include anti-
cardiolipin (ACA) and lupus anticoagulant (LAC).17
The arteries and veins of virtually any organ system
may be affected in APA, resulting in stroke, myocar-
dial infarction, pulmonary embolism and RVT. APA
accounts for 20% of recurrent RVT in young/middle-
aged men and women and may be seen with or with-
out renal artery thrombosis.18 Mechanisms by which
anti-phospholipid antibodies induce thrombosis and
loss of pregnancy include endothelial activation, in-
terference with placental anticoagulant protein-I
(annexin V) and anti-B2- glycoprotein-I antibodies.
Additionally there is induction of tissue factor or
monocyte chemo-attractant protein I, and inhibition
of the anticoagulant function of activated protein C
by auto-antibodies. The kidney appears to be a major
target organ in both primary and secondary APS.19
Occasionally APS may progress rapidly with de-
vastating consequences (catastrophic APS) such as
multi-organ failure and death. Antiphospholipid
antibodies are known to coexist with idiopathic mem-
branous nephropathy in approximately one fourth of
patients.20
Clinical manifestations
Early reports of RVT emphasized the presence of flank
pain, flank tenderness, microscopic haematuria, rapid
deterioration of renal function and worsening protein-
uria as the cardinal features of RVT.21 Harrison et al.
in 1956 reported that patients with RVT may either
present with more dramatic classical symptoms or
insidious/chronic symptoms manifested as peripheral
oedema.22
Acute onset RVT usually affects neonates and in-
fants following severe dehydration manifested as
dry mouth, scanty urine and loss of skin turgidity.
The clinical features suggestive of RVT include nau-
sea, vomiting, fever, flank pain, gross haematuria
and palpably enlarged kidneys. Other manifestations
include renal failure, thrombocytopenia and anaemia.
As loin pain and haematuria predominates the prob-
lem may be mistaken for renal colic or pyelonephri-
tis.23 Male children are affected twice as often as
females and the left renal vein is affected twice as
often as the right renal vein.24 Left sided RVT may
lead to gonadal vein thrombosis manifested as pelvic
congestion syndrom25 in females and painful swelling
of the left testis and varicocele in males.26
Acute onset RVT may also occur in association with
APS, injury to the renal vein during renal venography,trauma, post renal transplantation, surgery around
the renal vein and occasionally in nephrotic syn-
drome. Bilateral RVT or involvement of the solitary
kidney may present with features of acute renal fail-
ure. Following renal transplants both acute and
chronic variants of RVT are recognised.27
Investigations
Laboratory
There are no specific laboratory tests to diagnose RVT.
Imaging
In the absence of specific diagnostic laboratory tests
and paucity of clinical manifestations, imaging re-
mains the cornerstone of diagnosis. Radiological signs
vary according to the speed of onset and degree of oc-
clusion of the renal vein. In cases of rapid onset and
complete occlusion the affected kidney becomes
enlarged and reaches maximum dimensions within
one week. Subsequently however, there is a gradual
reduction in the renal size over next few weeks and
later renal atrophy. An ultrasound scan shows an
enlarged kidney and hyper-echogenic kidney in ap-
proximately 90% of the patients in the early phase of
acute RVT.28
Colour Doppler ultrasound has poor yield in de-
tecting segmental venous thrombosis, but is much su-
perior to ultrasound in detecting flow in the renal
artery and the renal vein. It is particularly useful for
screening. The Colour Doppler ultrasound is being
utilised widely to detect RVT in renal transplant
patients with a high degree of sensitivity.29
Findings on intravenous urography (IVU) vary
according to the clinical situation. With sudden and
complete venous occlusion the collecting system
may not be visualized due to poor excretion by the
affected kidney. However, in most cases due to the
development of collateral circulation contrast is ex-
creted by the kidney demonstrating a stretched and
distorted renal pelvis and calyces due to the
oedematous enlarged kidney in almost 80% patients.
Renal venous occlusion leads to the development of
varicosities in chronic RVT, which impart a notching
appearance to the ureter.28 During the late vascular
phase, collateral venous drainage around the kidney
may be seen.30
CT scan is currently the imaging of choice for diag-
nosing RVT as it is non-invasive, relatively less expen-
sive, can be performed quickly, and has a high
diagnostic accuracy. Simultaneous intravenous ad-
ministration of contrast (CT angiography) assists visu-
alization of the renal veins. Indirect radiographic
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RV enlargement; delayed, diminished, or absent
opacification of the collecting system; a persistent
nephrogram attributable to poor venous washout;
prolonged corticomedullary differentiation; thicken-
ing of renal fascia; and stranding of perinephric fat.
The sensitivity and specificity of CT angiography is
almost 100%. It can also demonstrate renal tumour
and other renal pathologies simultaneously. The dis-
advantages of CT include exposure to radiation and
use of nephrotoxic iodinated contrast media.31
Magnetic Resonance Angiography (MRA) is an al-
ternative imaging modality which has several advan-
tages over CT scan. It is non-invasive, avoids radiation
and use of nephrotoxic intravenous contrast agents. It
produces high contrast images of flowing blood, ves-
sel walls, kidneys and the surrounding tissues. In one
study, MRA could delineate the entire course of the
renal vessels in 88% of cases compared to 58% with
Colour Doppler ultrasound and 43% on spin-echo
MRI. Similarly the anatomic variants, vessel displace-
ment, collateral circulation and neoplastic vessel in-
filtration were demonstrated more accurately by
MRA.32 Disadvantages include, higher cost, need for
anaesthesia in children and claustrophobic adults
and marginally inferior sensitivity and specificity
compared to CT scan.33
Inferior venacavography and selective renal veno-
graphy is the definitive diagnostic test. A patent IVC
without any filling defects in conjunction with clear-
ance of the contrast by the renal vein practically rules
out the diagnosis of RVT. Valsalva maneuvour during
the study may facilitate the opacification of the renal
vein by slowing down the blood flow and hence clear-
ance of the contrast from the IVC. Findings indicative
of RVT include lack of washout of contrast or obvious
filling defects due to the presence of thrombus. Veno-
graphy is however, invasive, involves higher radia-
tion exposure and injection of iodinated contrast.
Selective renal venography also carries the potential
risk of causing de novo RVT due to venous injury. 34
DTPA Renal scan may show delayed clearance of
the tracer. Venographic phase of Tc-99 m MAG3 is
particularly useful but is non-specific. Renal Biopsy
performed for any other indications may show dilated
capillaries and venules.
Management
In the past, the treatment of RVTwas primarily surgi-
cal involving thrombectomy or nephrectomy. Both op-
tions are invasive and were associated with significant
complications. However, trends have changed over
Eur J Vasc Endovasc Surg Vol 34, August 2007the past decades from surgical to predominantly med-
ical management in the form of initial intravenous
and subsequent oral anticoagulation.35 Anticoagula-
tion therapy may improve renal function particularly
in cases of acute RVT, result in re-canalisation or com-
plete resolution of thrombus in the renal veins and
reduce the incidence of recurrent thromboembolic
complications. Minimally invasive interventions or
nephrectomy are employed in highly selected
patients.
Asymptomatic patients with unilateral RVT, espe-
cially in nephrotic syndrome, may not require any
specific treatment. In such patients, active surveillance
in conjunction with supportive measures to reduce
proteinuria including salt and protein restriction, di-
uretics and statins may partially reverse the hyper-
coagulability. Depending on the patient’s progress
corticosteroids, angiotensin converting enzyme inhib-
itors (ACEI), angiotensinogen II receptor blockers
(ARBs), cyclosporine, cytotoxic agents or mycopheno-
late and one of the statins may be required.36,37
However, if the patient’s condition deteriorates due
either to progression of thrombosis or embolism
active intervention should be considered.
Anticoagulation in symptomatic patients should be
initiated early to prevent propagation of thrombus
and potential serious thromboembolism.38 Irrespec-
tive of whether RVT is acute or chronic, unilateral or
bilateral, initial anticoagulation is achieved with par-
enteral heparin. Patients are subsequently switched
over to warfarin, within 3 to 10 days and continued
long-term. Warfarin has unique pharmacodynamic
properties affecting its absorption, protein binding,
metabolism and excretion. It interacts with many
other drugs and hence requires careful monitoring
and tailoring of the treatment to the individual’s
needs according to the patient’s clinical situation, sen-
sitivity and metabolism.
Duration of anticoagulation therapy varies from
a minimum of a year to lifelong, depending upon re-
currence of RVT or continued presence of risk factors.
The degree of hypo-albuminaemia is considered
a good indicator of hypercoagulabity. It is recommen-
ded that patients should be treated with anticoagu-
lants as long as serum albumin remains below
2.5 grams/L but recurrent thrombosis can occur on
discontinuation of anticoagulation therapy. Therefore
it is advisable to maintain anticoagulation until com-
plete resolution of the nephrotic syndrome.39
The anticoagulation therapy aims at achieving an
INR of 2.5 (range 2.0 to 3.0). Un-fractionated heparin
is usually administered as a loading dose of 5000 IU
intravenously, followed by 20 000 to 40 000 IU per 24
hours. APTT is monitored twice daily until stable.
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induced thrombocytopenia and serious haemorrhage
has been reported in 2% and 3% of patients
respectively.40,41
Low molecular weight heparins (LMWHep) are
becoming increasingly popular because of higher
bioavailability, fewer complications, convenience of
subcutaneous administration and cost-effectiveness
as these can be given in the outpatient setting. The rec-
ommended dose of the commonly used agent Enoxa-
parin Sodium (Clexane) in this setting is 1.5 mg/Kg
(150 units) daily.38
Specific treatment for the underlying disorders
should be instituted simultaneously e.g. steroids/
immuno-suppression therapy in APS. Some patients
especially neonates with bilateral RVT and renal fail-
ure may need urgent and aggressive supportive ther-
apy including renal replacement therapy (dialysis).
Likewise patients with catastrophic APS may require
immunosuppressant, plasmaphresis and intra-venous
immunoglobulin in addition to vigorous supportive
measures according to the individual needs.
Selected cases (Table 2) of RVT are suitable for
thrombectomy (mechanical thrombectomy) and/or
thrombolysis (chemical thrombectomy). The later
can be administered systemically or locally. These in-
terventions are performed percutaneously at an early
stage, to prevent irreversible damage to the kidney.
Administration of thrombolytic agents via a catheter
is associated with fewer systemic side effects com-
pared to systemic thrombolytic therapy. Commonly
used thrombolytic agents include streptokinase, uro-
kinase26 and, more recently, recombinant tissue plas-
minogen activators.42 Thrombolytic therapy results
in rapid improvement in renal function and has low
morbidity when used appropriately.43,44
Local thrombolytic therapy can be combined with
mechanical thrombectomy to achieve complete and
rapid clearance of the thrombus. The most appropri-
ate cases for such a combined radiological interven-
tion would be bilateral renal vein involvement,
thrombosis of a solitary native kidney or a renal trans-
plant and cases with large thrombus burden where
a single modality treatment may not efficiently restore
Table 2. Indications of thrombectomy/thrombolysis in RVT42,44
Treatment failure while on adequate anticoagulation
Onset of complications e.g. pulmonary embolism
Bilateral RVT
Acute renal failure (Bilateral RVT/RVT in solitary kidney)
Extension into inferior vena cava
Contraindication to systemic anticoagulant therapy.
Renal transplant
Severe, persistent flank painvenous circulation. Patients should then be main-
tained on systemic anticoagulation.44,45
A case of RVT associated with sub-hepatic IVC
thombosis has been successfully treated with stenting
of the IVC. Another case with a similar clinical situa-
tion has been managed by renal to inferior mesenteric
vein diversion.46,47 Rarely, nephrectomy may be re-
quired as a life-saving measure. This is indicated for
renal allograft rupture, complete necrosis of the kid-
ney with impending rupture or as a definitive form
of therapy in cases of renal cell carcinoma when the
contra-lateral kidney is normal.48
IVC filters may be considered in high risk patients
in whom the primary aim of treatment is the preven-
tion of pulmonary embolism originating from RVT or
from associated thrombosis of the IVC. These have
been employed in thrombosis of the IVC in associa-
tion with germ cell tumours, adrenal tumours, renal
injuries and SLE.49 Use of these filters may also be jus-
tified in patients undergoing thrombolytic therapy to
prevent pulmonary embolism.50
Prognosis
The prognosis of RVT depends on multiple factors
(Table 3). Review of the early literature highlights
alarmingly high mortality (64%) due to the fact that
most of the reported data were obtained from autop-
sies.51 Common causes of high mortality were renal
failure, recurrent thrombo-embolism and sepsis. Prog-
nosis of the condition however, has improved over the
last few decades due to availability of dialysis, better
diagnostic tests and rational use of anticoagulation.
Laville et al. reported 40% mortality in the first
six months primarily due either to haemorrhagic
complications or sepsis in a study of 27 patients with
RVT associated with nephrotic syndrome. Amongst
survivors (n¼ 16), nephrotic syndrome resolved in
(n¼ 12) 75% of patients and renal function remained
stable during follow up. Having analysed various
prognostic factors, they concluded that age had no
influence on survival or long term renal function but
patients older than 55 years were more likely to de-
velop acute renal failure (ARF). Prognosis of patients
with membranous glomerulonephritis is more favour-
able as they are less likely to develop ARF. Similarly
Table 3. Prognostic factors in RVT 3,52,14,44
The baseline renal function at the onset
Status of contralateral kidney and its vasculature
The speed of onset of the RVT/development of adequate collaterals
Adequacy of management
Severity and progress of the original disease process.
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with RVTassociated with other forms of glomerulone-
phritis or primary renal vein thrombosis. The progno-
sis is not influenced by unilateral or bilateral renal
vein involvement. Normal baseline renal function at
presentation appears to be the most important prog-
nostic factor associated with favourable outcome. Re-
covery of renal function does not necessarily follow
renal vein re-canalisation particularly in cases of
chronic RVT.52
Important efforts have been made to evaluate post
thrombotic outcomes in children. Large cohort studies
have confirmed low frequency of recurrent thrombo-
embolism, but have shown lack of resolution of throm-
bus following standard duration anti-coagulation
therapy in as many as 50% of the patients. Patients
may develop post-thrombotic syndrome characterised
by lower limb varices and symptoms of venous hyper-
tension inmore than one third of children.53,54 Heparin
therapy has been found to be very beneficial in preserv-
ing renal function and reversing any renal dysfunction.
Long-term renal function impairment has been re-
ported in 100% of those who did not receive heparin
compared to 33% of those who received heparin.3
Conclusion
RVT is under reported as some cases go unrecognised
due to lack of clinical manifestations. A multinational
multi-centre therapeutic trial with long term follow-
up is required to determine the optimal diagnostic
and therapeutic approach.54,55 Current trends favour
CT scan as the diagnostic modality of choice. Antico-
agulation has emerged as the mainstay of treatment in
the majority of the cases. Radiological interventions
including thrombolysis with or without thrombec-
tomy and ablative surgical measures like nephrec-
tomy are only required in highly selected cases.
Advances in the prediction of post thrombotic out-
comes are being made to facilitate a risk-stratified
approach in anti-thrombotic management to achieve
improvements in long-term outcomes.53
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